Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: A cost-effectiveness analysis

Bristow, Robert E.; Santillan, Antonio; Salani, Ritu; Díaz-Montes, Teresa; Giuntoli, Robert L.; Meisner, Benjamin C.; Armstrong, Deborah K.; Frick, Kevin D.

doi:10.1016/j.ygyno.2007.05.043

Cited by 47 publications

(41 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…119,120 Recent studies have shown that intraperitoneal (IP) administration can be more effective than a similar concentration administered intravenously for some solid tumor therapy. [121][122][123] IP administration has been shown to be more effective in terms of cost versus the survival rate, making it an interesting economic choice. One drawback of IP administration comes from the higher, localized concentration of the drug inducing toxicity at the injection site.…”

Section: Local Injectionmentioning

confidence: 99%

Polymeric nanoparticles for colon cancer therapy: overview and perspectives

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Local Injectionmentioning

confidence: 99%

Polymeric nanoparticles for colon cancer therapy: overview and perspectives

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Only one of the 27 studies (4%) identified in this review incorporated direct measures of QoL into the cost assessment [71] via surveys of participating patients. About half of the math modeling studies used "utility factors" to incorporate QoL-related adjustments.…”

Section: Resultsmentioning

confidence: 99%

Do current approaches to assessing therapy related adverse events align with the needs of long-term cancer patients and survivors?

Pettit

Kirch

2018

Cardio-Oncology

View full text Add to dashboard Cite

The increasing efficacy of cancer therapeutics means that the timespan of cancer therapy administration is undergoing a transition to increasingly long-term settings. Unfortunately, chronic therapy-related adverse health events are an unintended, but not infrequent, outcome of these life-saving therapies. Historically, the cardio-oncology field has evolved as retrospective effort to understand the scope, mechanisms, and impact of treatment-related toxicities that were already impacting patients. This review explores whether current systemic approaches to detecting, reporting, tracking, and communicating AEs are better positioned to provide more proactive or concurrent information to mitigate the impact of AE's on patient health and quality of life. Because the existing tools and frameworks for capturing these effects are not specific to cardiology, this study looks broadly at the landscape of approaches and assumptions. This review finds evidence of increasing focus on the provision of actionable information to support long-term health and quality of life for survivors and those on chronic therapy. However, the current means to assess and support the impact of this burden on patients and the healthcare system are often of limited relevance for an increasingly long-lived survivor and patient population.

show abstract

“…Administering adjuvant platinum-taxane chemotherapy via the intraperitoneal (IP) route over the traditional intravenous (IV) route was evaluated by two studies [29,30]. Treatment arms that were compared in both studies were based on GOG-158 [51] and GOG-172 [52] Table 2 for 2014 USD equivalent ICERs).…”

Section: Intraperitoneal Compared With Intravenous Route Of Administrmentioning

confidence: 99%

“…Quality-of-life adjustment due to treatments administered and associated adverse events was carried out for 13 studies. Three studies used utility values estimated from Functional Assessment of Cancer Therapy-General/ Ovarian quality of life questionnaire [29,30,42], while Barnett et al assessed utilities from the EORTC quality of life questionnaire [32]. Two studies evaluating treatments among platinum-sensitive ovarian cancer patients applied utilities obtained from the OVA-301 study which utilized the EuroQol EQ-5D questionnaire [40,43].…”

Section: Quality Assessmentmentioning

confidence: 99%

“…Almost all studies stated (89 %) a perspective, of which four studies considered a societal perspective. Two studies considered wages lost along with caregiver costs [29,34], one study only included caregiver cost [30], and the remaining study considered only transportation costs [41]. Direct costs most commonly included were related to treatment (i.e., drug cost), treatment administration, hospitalization, and adverse events.…”

Section: Quality Assessmentmentioning

confidence: 99%

See 1 more Smart Citation

Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review

Poonawalla

Parikh

et al. 2015

PharmacoEconomics

View full text Add to dashboard Cite

Despite varying methodological approaches and multiple sources for cost and effectiveness inputs, this systematic review demonstrated that standard platinum-taxane combination chemotherapy for first-line treatment was most cost-effective. There was unanimous agreement that bevacizumab was not a cost-effective front-line therapy compared with platinum-taxane combination for the overall ovarian cancer population, though its use in the high-use population may yield better value. For second-line treatment, platinum-based chemotherapy remained cost-effective among patients with recurrent platinum-sensitive disease, while there was limited evidence to conclude the most valuable treatment alternative among patients with recurrent platinum-resistant disease. Future research incorporating real-world data is essential to corroborate findings from trial-based economic evaluations. In addition, for improving consistency in reporting and quality of studies, incorporating QALYs in this population is important, especially since chemotherapy is administered for lengthy periods of time.

show abstract

Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: A cost-effectiveness analysis

Cited by 47 publications

References 12 publications

Polymeric nanoparticles for colon cancer therapy: overview and perspectives

Polymeric nanoparticles for colon cancer therapy: overview and perspectives

Do current approaches to assessing therapy related adverse events align with the needs of long-term cancer patients and survivors?

Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review

Contact Info

Product

Resources

About